$4.12
+0.09 (+2.23%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CYCN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
11 interventional · 4 with posted results
Held by 2 tracked-famous managers (Balyasny Asset Management L.P., CITADEL ADVISORS LLC) · FINRA short interest 2.6 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)NCT03285178results2023-07-21Double-Blind Treatment: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: IW-1701, Placebo | Sickle Cell Disease | 88 | 2020-07-22actual | 2023-07-21 |
| A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy VolunteersNCT03892499Maximum Observed Plasma Concentration (Cmax) of olinciguatOpen-label · Other | Phase 1 | Completed | Drug: Olinciguat, Itraconazole | Healthy | 24 | 2019-06-23actual | 2019-07-15 |
| A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Praliciguat in Healthy Male VolunteersNCT03818295Amount of total radioactivity excreted in urine (Aeu) and feces (Aef)Open-label · Other | Phase 1 | Completed | Drug: [14C]-praliciguat | Healthy Volunteers | 8 | 2019-04-24actual | 2019-06-19 |
| A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male VolunteersNCT03795519Amount of total radioactivity excreted in urine (Aeu) and feces (Aef)Open-label · Other | Phase 1 | Completed | Drug: [14C]-olinciguat | Healthy Volunteers | 8 | 2019-02-27actual | 2019-04-03 |
| A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of Praliciguat (IW-1973) in Healthy VolunteersNCT03499106Area Under the Plasma Concentration Time Curve of IW-1973 From Time Zero Extrapolated to Infinity (AUC[0-inf])Open-label · Other | Phase 1 | Completed | Drug: IW-1973, Itraconazole | Healthy | 24 | 2018-07-06actual | 2019-04-03 |
| Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II AchalasiaNCT02931565results2021-05-04Number of Participants With Treatment Emergent Adverse Events (TEAEs), Deaths, Serious Adverse Events (SAEs), and Adverse Events Resulting in Study Drug Discontinuation (ADOs)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The study was prematurely terminated due to enrollment challenges. | Drug: Olinciguat, Matching Placebo | Achalasia | 9 | 2018-05-01actual | 2021-05-04 |
| Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and HypertensionNCT03091920results2020-08-31Change From Study Baseline Over Time in Supine Systolic Blood PressureRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: IW-1973, Placebo | Diabetes Mellitus, Type 2, Hypertension | 26 | 2017-08-03actual | 2020-08-31 |
| A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and HypertensionNCT02906579results2020-04-16Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Due to TEAEsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Matching Placebo, IW-1973 | Diabetes Mellitus, Type 2, Hypertension | 11 | 2017-03-17actual | 2020-04-16 |
| A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy SubjectsNCT02792998Treatment Emergent Adverse EventRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: IW-1701, Placebo | Healthy | 67 | Nov 2016actual | 2019-04-03 |
| Trial of IW-1973 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy VolunteersNCT02616861Treatment Emergent Adverse EventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: IW-1973, Matching Placebo Tablet | Healthy | 54 | May 2016actual | 2019-04-03 |
| Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy VolunteersNCT02572349Assessment of the safety and tolerability of IW-1701 in healthy subjects via adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: IW-1701, Matching Placebo | Healthy | 24 | Dec 2015actual | 2019-04-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19